These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
259 related articles for article (PubMed ID: 2249319)
1. [Pulmonary changes in progressive systemic sclerosis]. Yao WZ Zhonghua Jie He He Hu Xi Za Zhi; 1990 Jun; 13(3):157-9, 191. PubMed ID: 2249319 [TBL] [Abstract][Full Text] [Related]
2. Lung involvement in systemic sclerosis. Silver RM; Miller KS Rheum Dis Clin North Am; 1990 Feb; 16(1):199-216. PubMed ID: 2406808 [TBL] [Abstract][Full Text] [Related]
3. Pulmonary functions in children with progressive systemic sclerosis. Garty BZ; Athreya BH; Wilmott R; Scarpa N; Doughty R; Douglas SD Pediatrics; 1991 Dec; 88(6):1161-7. PubMed ID: 1956732 [TBL] [Abstract][Full Text] [Related]
4. [The correlations of respiratory function tests, chest roentgenographic manifestations and respiratory symptoms in the patients with systemic sclerosis, using a scoring-method for symptoms]. Kikuchi K; Igarashi A; Ishibashi Y; Inokuma S; Takehara K Nihon Hifuka Gakkai Zasshi; 1990 May; 100(6):695-700. PubMed ID: 2214236 [TBL] [Abstract][Full Text] [Related]
5. Static lung mechanics in patients of progressive systemic sclerosis without obvious pulmonary involvement. Gupta D; Aggarwal AN; Sud A; Jindal SK Indian J Chest Dis Allied Sci; 2001; 43(2):97-101. PubMed ID: 11529415 [TBL] [Abstract][Full Text] [Related]
6. [Pulmonary involvement in sclerodermia]. Paone G; Di Michele L; Mattia P; Tonnarini R; Lucifora V; Fiorucci F Minerva Med; 1994 Jun; 85(6):293-300. PubMed ID: 8084431 [TBL] [Abstract][Full Text] [Related]
7. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Khanna D; Clements PJ; Furst DE; Chon Y; Elashoff R; Roth MD; Sterz MG; Chung J; FitzGerald JD; Seibold JR; Varga J; Theodore A; Wigley FM; Silver RM; Steen VD; Mayes MD; Connolly MK; Fessler BJ; Rothfield NF; Mubarak K; Molitor J; Tashkin DP; Arthritis Rheum; 2005 Feb; 52(2):592-600. PubMed ID: 15692967 [TBL] [Abstract][Full Text] [Related]
8. Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis. Jacobsen S; Ullman S; Shen GQ; Wiik A; Halberg P J Rheumatol; 2001 Nov; 28(11):2454-9. PubMed ID: 11708418 [TBL] [Abstract][Full Text] [Related]
9. Non-invasive diagnostic and functional evaluation of cardiac and pulmonary involvement in systemic sclerosis. Sergiacomi G; De Nardo D; Capria A; Manenti G; Fabiano S; Borzi M; De Sanctis G; Konda D; Sperandio M; Schillaci O; Masala S; Simonetti G; Fontana L In Vivo; 2004; 18(2):229-35. PubMed ID: 15113051 [TBL] [Abstract][Full Text] [Related]
10. Role of inflammation in the lung disease of systemic sclerosis: comparison with idiopathic pulmonary fibrosis. Owens GR; Paradis IL; Gryzan S; Medsger TA; Follansbee WP; Klein HA; Dauber JH J Lab Clin Med; 1986 Mar; 107(3):253-60. PubMed ID: 3950467 [TBL] [Abstract][Full Text] [Related]
11. [Collageno-vascular diseases and interstitial pulmonary fibrosis. An analysis of diagnostic tests]. Baldi S; Rapellino M; Libertucci D; Obert R; Scappaticci E; Coni F; Revello F; Oliaro A; Botto-Micca F Minerva Med; 1987 Sep; 78(17):1277-80. PubMed ID: 3670681 [TBL] [Abstract][Full Text] [Related]
12. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Hoyles RK; Ellis RW; Wellsbury J; Lees B; Newlands P; Goh NS; Roberts C; Desai S; Herrick AL; McHugh NJ; Foley NM; Pearson SB; Emery P; Veale DJ; Denton CP; Wells AU; Black CM; du Bois RM Arthritis Rheum; 2006 Dec; 54(12):3962-70. PubMed ID: 17133610 [TBL] [Abstract][Full Text] [Related]
13. Clinical significance of soluble CD31 in patients with systemic sclerosis (SSc): association with limited cutaneous SSc. Sato S; Komura K; Hasegawa M; Fujimoto M; Takehara K J Rheumatol; 2001 Nov; 28(11):2460-5. PubMed ID: 11708419 [TBL] [Abstract][Full Text] [Related]
14. Latent pulmonary inflammation in patients with systemic sclerosis. Sánchez-Vidaurre S; Simeón CP; Cruz MJ; Fonollosa V; Vilardell M; Morell F; Muñoz X Arch Bronconeumol; 2012 Jan; 48(1):8-13. PubMed ID: 22133713 [TBL] [Abstract][Full Text] [Related]
15. [Two cases of intrapulmonary lymph node associated with either progressive systemic sclerosis or idiopathic pulmonary fibrosis]. Yoshitomi A; Sato A; Toyoshima M; Suganuma H; Imokawa S; Tamura R; Suda T; Yagi T; Hayakawa H; Chida K Nihon Kyobu Shikkan Gakkai Zasshi; 1995 Sep; 33(9):1003-8. PubMed ID: 8538080 [TBL] [Abstract][Full Text] [Related]
16. The pulmonary manifestations of systemic sclerosis. Phillips B; Powell RD; Gammon D; Woodring JH J Ky Med Assoc; 1985 Nov; 83(11):611-6. PubMed ID: 4067388 [No Abstract] [Full Text] [Related]
17. Serial changes in scleroderma and idiopathic interstitial lung disease. Colp CR; Riker J; Williams MH Arch Intern Med; 1973 Oct; 132(4):506-15. PubMed ID: 4742404 [No Abstract] [Full Text] [Related]
18. Progression of childhood linear scleroderma to fatal systemic sclerosis. Mayorquin FJ; McCurley TL; Levernier JE; Myers LK; Becker JA; Graham TP; Pincus T J Rheumatol; 1994 Oct; 21(10):1955-7. PubMed ID: 7837166 [TBL] [Abstract][Full Text] [Related]
19. Pulmonary arterial hypertension and severe pulmonary fibrosis in systemic sclerosis patients with a nucleolar antibody. Steen VD; Lucas M; Fertig N; Medsger TA J Rheumatol; 2007 Nov; 34(11):2230-5. PubMed ID: 17937469 [TBL] [Abstract][Full Text] [Related]
20. A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease. Várai G; Earle L; Jimenez SA; Steiner RM; Varga J J Rheumatol; 1998 Jul; 25(7):1325-9. PubMed ID: 9676764 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]